[Comment] Selective amylin receptor agonism: promise beyond incretins

00:00 - 06 Nov 2025

Obesity is increasingly recognised as a complex and heterogeneous disease arising from the interplay of genetic, behavioural, environmental, and societal factors. Its effective management demands an integrated approach encompassing lifestyle modification and psychological, medical, and surgical interventions, as well as policy measures that address obesogenic environments.1 Among all these treatment pillars, incretin-based therapies have contributed substantially in the management of obesity. Nevertheless, treatment responses with these drugs are variable, and gastrointestinal adverse effects often limit long-term adherence.